Scan Under the Radar for Promising Biotechs Kapitall Blog (blog) Vice president of sales Michael Crum arrived in January after 13 years at Genentech (Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments including Rituxan (rituximab), Avastin (bevacizumab) and Herceptin (trastuzumab). A total ... |
